The initial success of Viagra undeniably reshaped the drug landscape, but investing in companies strongly reliant on generic versions presents a challenging picture. Although early returns were significant, the expiration of patents and the appearance of discounted alternatives have eroded market share. Consequently, a thorough evaluation of curren